BMRA Biomerica, Inc.
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. It focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
IRS number
952645573
BMRA stock data
()
Investment data
Securities sold
Number of investors
Calendar
14 Apr 20
4 Jul 20
31 May 21
News
Company financial data Financial data
| Quarter (USD) | Feb 20 | Nov 19 | Aug 19 | May 19 | |
|---|---|---|---|---|---|
| Revenue | 1.18M | 1.6M | 1.19M | 1.17M | |
| Net income | -860.93K | -485.26K | -506.3K | -785.33K | |
| Diluted EPS | -0.09 | -0.05 | -0.05 | -0.08 | |
| Net profit margin | -73.15% | -30.40% | -42.39% | -67.36% | |
| Operating income | -914.89K | -489.74K | -509.56K | -764.82K | |
| Net change in cash | 1.54M | 43.44K | 120.77K | -231.15K | |
| Cash on hand | 2.39M | 850.99K | 807.55K | 686.79K | |
| Cost of revenue | 964.91K | 1.13M | 827.11K | 985.05K |
| Annual (USD) | May 19 | May 18 | May 17 | May 16 | |
|---|---|---|---|---|---|
| Revenue | 5.2M | 5.56M | 5.79M | 5.14M | |
| Net income | -2.39M | -1.47M | -908.56K | -1.5M | |
| Diluted EPS | -0.26 | -0.17 | -0.11 | -0.2 | |
| Net profit margin | -46.01% | -26.34% | -15.69% | -29.18% | |
| Operating income | -2.41M | -1.48M | -954.63K | -826.95K | |
| Net change in cash | -518.12K | -20.56K | -663.46K | 800.62K | |
| Cash on hand | 686.79K | 1.2M | 1.23M | 1.89M | |
| Cost of revenue | 3.91M | 3.81M | 3.77M | 3.62M |
Financial data from Biomerica earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 21 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.1063 | 5,000 | 40.53K | 8,700 |
| 17 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.077 | 2,454 | 19.82K | 13,700 |
| 17 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.07 | 1,302 | 10.51K | 16,154 |
| 17 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.05 | 1,076 | 8.66K | 17,456 |
| 17 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.06 | 100 | 806 | 18,532 |
| 17 Apr 20 | Sirgo Mark A | Common Stock | Sell | Dispose S | No | 8.09 | 68 | 550.12 | 18,632 |
| 1 Apr 20 | Barbieri Allen | Common Stock | Gift | Dispose G | No | 0 | 23,000 | 0 | 137,289 |
| 28 Feb 20 | Zackary S. Irani | Common Stock | Other | Aquire J | No | 2.85 | 78,431 | 223.53K | 1,002,160 |
| 2 Jan 20 | Janet Moore | Common Stock | Gift | Dispose G | No | 0 | 20,000 | 0 | 101,720 |
| 19 Dec 19 | Zackary S. Irani | Non Qualified Stock Option Common Stock | Grant | Aquire A | No | 2.81 | 125,000 | 351.25K | 555,000 |
Institutional ownership Q1 2020
4.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 22 |
| Opened positions | 13 |
| Closed positions | 2 |
| Increased positions | 5 |
| Reduced positions | 2 |
13F shares |
Current |
|---|---|
| Total value | 3.85M |
| Total shares | 513.29K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Vanguard | 293.79K | $2.1M |
| Geode Capital Management | 49.33K | $352K |
| Heritage Investors Management | 38.15K | $273K |
| Perritt Capital Management | 30K | $215K |
| Millennium Management | 26.22K | $187K |
| Creative Planning | 17K | $122K |
| MS Morgan Stanley | 16.04K | $115K |
| GS The Goldman Sachs Group, Inc. | 10.54K | $75K |
| Bard Associates | 10K | $72K |
| WFC Wells Fargo & Co. | 7.95K | $56K |
Financial report summary
?Management Discussion
- Consolidated net sales for Biomerica were $1,176,889 for the three months ended February 29, 2020 as compared to $1,261,161 for the three-month period ended February 28, 2019. This represents a decrease of $84,272 or 6.7%. For the nine-month period ended February 29, 2020 as compared to the nine-month period ended February 28, 2019, net sales were $3,967,712 as compared to $4,034,822. This represents a decrease of $67,110 or 1.7%. The decrease for the three-month period and for the nine-month period was primarily due to lower sales to China as a result of the coronavirus in China during the quarter ended February 29, 2020.
- For the three months ended February 29, 2020 as compared to the three months ended February 28, 2019, cost of sales increased as a percentage of sales from 71.0% of sales, or $895,237, to 82.0% of sales, or $964,910. For the nine months ended February 29, 2020 as compared to February 28, 2019, cost of sales as a percentage of sales increased from 72.5% of sales, or $2,923,615 to 73.6% of sales, or $2,919,557. The increase to cost of goods as a percentage of sales for the three and nine months were due to increased material costs, higher wages and benefits’ costs as well as fixed costs in relation to lower sales during the quarter and nine months ended February 29, 2020.
- For the three months ended February 29, 2020 compared to February 28, 2019, selling, general and administrative expenses increased by $77,515, or 13.5%. For the nine months ended February 29, 2020 as compared to February 28, 2019, selling, general and administrative expenses increased by $225,653, or 15.2%. The increase for the quarter and nine months ended February 29, 2020 as compared to February 28, 2019, was primarily due to an increase of non-cash option expense, and increased wages and consulting fees.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
absenteeism, accurate, aimed, alternative, anniversary, ATM, Authorization, avoid, begun, breakdown, broker, Cap, carefully, case, CEO, chain, closure, complimentary, confirmed, consecutive, consent, conversion, convert, converted, convertible, decision, demonstrate, depend, depression, directed, Disaggregation, dissolution, efficacy, eligible, ELISA, Emergency, entitled, equal, error, eventual, exempt, EXTENSIVE, face, fall, finger, format, found, gain, Gaining, global, holder, home, Hubei, Icahn, IgG, IgM, ii, implement, implemented, ineffective, infection, inoperable, insolvency, integrate, laboratory, license, licensed, liquidation, logistical, LP, marketplace, Master, Medicine, microplate, million, Mount, negotiated, outbreak, Palm, pandemic, participating, partner, PCR, preferred, prick, prohibit, promising, proposed, Province, qualitative, Rapid, recession, refuse, render, resale, risk, royalty, run, safe, scale, School, serological, serum, shelter, show, Sinai, SOCIETAL, speed, spread, spreading, subscribed, subscription, sufficiently, system, thereon, thereunder, trained, transaction, travel, treating, Ultimately, unable, unaware, unforeseen, unpaid, validate, version, view, volume, widespread, winding, world, Wuhan, York
Removed:
abroad, alleging, anticipate, arise, border, brought, carried, climate, competition, competitive, complying, concentrated, counter, degradation, desired, difficulty, discussed, disruption, enactment, escalation, Europe, exhaustive, expansion, fluctuate, foreseeable, gastroenterology, high, highlight, hire, imposed, inability, incorporated, key, labor, lead, macroeconomic, manage, meant, mix, negative, obtain, obtaining, occasion, October, operate, paying, performance, predict, previously, profitability, protracted, receiving, reduced, reference, response, shutdown, significantly, spending, subject, substantially, support, terrorist, unpredictably
Financial reports
10-Q
2020 Q3
Quarterly report
14 Apr 20
10-Q
2020 Q2
Quarterly report
14 Jan 20
10-Q
2020 Q1
Quarterly report
15 Oct 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 Apr 19
10-Q
2019 Q2
Quarterly report
14 Jan 19
10-Q
2019 Q1
Quarterly report
15 Oct 18
10-K
2018 FY
Annual report
29 Aug 18
10-Q
2018 Q3
Quarterly report
16 Apr 18
10-Q/A
2018 Q2
Quarterly report (amended)
17 Jan 18
Current reports
8-K
Regulation FD Disclosure
17 Jun 20
8-K
Regulation FD Disclosure
2 Jun 20
8-K
Regulation FD Disclosure
9 May 20
8-K
Entry into a Material Definitive Agreement
6 Apr 20
8-K
Other Events
20 Mar 20
8-K
Biomerica Begins Shipping Samples of 10 Minute Test for COVID-19 Virus Exposure
18 Mar 20
8-K
Biomerica Announces $2.0 Million Investment by Palm Global Small Cap Master Fund
27 Feb 20
8-K
Regulation FD Disclosure
9 Jan 20
8-K
Submission of Matters to a Vote of Security Holders
13 Dec 19
8-K
Other Events
4 Sep 19
Registration and prospectus
424B5
Prospectus supplement for primary offering
20 Mar 20
D
$2M in equity, sold $2M, 1 investor
27 Feb 20
S-8
Registration of securities for employees
10 May 18
424B5
Prospectus supplement for primary offering
4 Dec 17
S-3
Shelf registration
30 Jun 17
8-A12B
Registration of securities on exchange
23 Aug 16
S-8
Registration of securities for employees
22 May 15
S-8
Registration of securities for employees
9 Feb 12
S-8
Registration of securities for employees
30 May 07
REGDEX
Notice of sale of securities
12 Jun 06
Proxies
DEF 14A
Definitive proxy
24 Sep 19
DEF 14A
Definitive proxy
28 Sep 18
DEF 14A
Definitive proxy
28 Sep 17
DEF 14A
Definitive proxy
28 Sep 16
DEF 14A
Definitive proxy
28 Sep 15
DEF 14A
Definitive proxy
29 Sep 14
DEF 14A
Definitive proxy
30 Sep 13
DEF 14A
Definitive proxy
28 Sep 12
DEF 14A
Definitive proxy
28 Sep 11
DEF 14A
Definitive proxy
29 Sep 10
Other
EFFECT
Notice of effectiveness
20 Jul 17
CORRESP
Correspondence with SEC
18 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
UPLOAD
Letter from SEC
17 Mar 09
CORRESP
Correspondence with SEC
16 Mar 09
CORRESP
Correspondence with SEC
4 Mar 09
UPLOAD
Letter from SEC
4 Mar 09
UPLOAD
Letter from SEC
20 Feb 09
UPLOAD
Letter from SEC
14 Apr 05
CORRESP
Correspondence with SEC
7 Apr 05
Ownership
4
BIOMERICA / Mark A Sirgo ownership change
21 Apr 20
4
BIOMERICA / ALLEN BARBIERI ownership change
3 Apr 20
SC 13D
Biomerica Inc
4 Mar 20
4
BIOMERICA / Zackary S. Irani ownership change
3 Mar 20
4
BIOMERICA / JANET MOORE ownership change
6 Jan 20
SC 13G
Biomerica Inc
6 Jan 20
4
BIOMERICA / Zackary S. Irani ownership change
23 Dec 19
4
BIOMERICA / Mark A Sirgo ownership change
23 Dec 19
4
BIOMERICA / ALLEN BARBIERI ownership change
23 Dec 19
4
BIOMERICA / FRANCIS CANO ownership change
23 Dec 19